NGR-hTNF is an experimental antitumor drug designed to act on tumor blood vessels. It is a recombinant protein made by fusing the peptide CNGRCG to human tumor necrosis factor alpha. According to the source, it was in phase III clinical trials for relapsed malignant pleural mesothelioma, the cancer caused by exposure to asbestos, in 35 clinical centers across Europe, the United States, Canada and Egypt, and it was also being studied alone or with chemotherapy in four randomized phase II trials in other solid tumors. It has been granted orphan drug designation in both Europe and the United States. It is an investigational product, and nothing here is medical advice.
Facts
Classification
Approval StatusInvestigational / Clinical Trial 1 ATC ClassL: Antineoplastic and Immunomodulating Agents 1 Route of Administration Mechanism of ActionVascular-targeting drug that increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment 2 Connections
Long-Form Articles
Treats
Source NGR-hTNF (antitumor recombinant protein) (Wikipedia)
Sources
1. NGR-hTNF (antitumor recombinant protein) (Wikipedia)
Lead paragraph
NGR-hTNF is an experimental antitumor drug designed to act on tumor blood vessels.
Treats: Mesothelioma, Lead paragraph [treats]
It is currently undergoing Phase III clinical trials for treatment of malignant pleural mesothelioma caused by exposure to asbestos.
View the Source2. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015)
Abstract, Methods, randomisation sentence
Participants were randomly assigned to receive weekly NGR-hTNF 0·8 μg/m2 intravenously plus best investigator choice
Abstract, Interpretation, mechanism sentence
NGR-hTNF is a vascular-targeting drug that increases penetration of intratumoral chemotherapy
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.